PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.

Patel, S. P.,Kurzrock, R.; Mol. Cancer Ther.. 2015 Feb 20.

CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1.

Osada, T.,Patel, S. P.,Hammond, S. A.,Osada, K.,Morse, M. A.,Lyerly, H. K.; Cancer Immunol. Immunother.. 2015 Mar 07.

Best practices for the Management of Local-regional Recurrent Chordoma. A Position Paper by the Chordoma Global Consensus Group.

Stacchiotti, S.,Gronchi, A.,Fossati, P.,Akiyama, T.,Alapetite, C.,Baumann, M.,Blay, J. Y.,Bolle, S.,Boriani, S.,Bruzzi, P.,Capanna, R.,Caraceni, A.,Casadei, R.,Colia, ...; Ann. Oncol.. 2017 Feb 12. CEA/CD3-bispecific T cell-engaging (BiTE) antibody-